Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:17:48.331Z.
Calculation as of: 2026-10-06T16:17:48.331Z.
Quote observation: 2026-10-06T16:15:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$993.23M
PS Ratio
2.94
TTM Avg
4.81
3Y Avg
13.09
5Y Avg
21.39
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $946.97M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $954.24M | 12.36 | 10.87 | 10.12 | 10.12 |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $938.53M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $932.69M | 9.15 | 7.97 | 9.20 | 9.20 |
| HealthStream, Inc. (HSTM)vs › | $913.12M | 2.84 | 2.39 | 2.83 | 2.81 |
| Aktis Oncology, Inc. (AKTS)vs › | $987.92M | 98.20 | 127.87 | 127.87 | 127.87 |
| Pacira BioSciences, Inc. (PCRX)vs › | $984.16M | 1.32 | 1.39 | 1.65 | 2.62 |
| MeiraGTx Holdings plc (MGTX)vs › | $991.26M | 2.49 | 15.04 | 25.67 | 23.89 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $993.23M | 2.94 | 4.81 | 13.09 | 21.39 |
| Bioventus Inc. (BVS)vs › | $899.69M | 1.55 | 1.18 | 0.98 | 0.92 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
